



SciGen signs US\$145m distribution agreement of hepatitis B vaccine in China

Sydney, Australia. 10 October 2005. ASX listed biopharmaceutical company SciGen Ltd (ASX:SIE) today announced the closure of a commercialization agreement with Hefei Life Science Park Investment & Development Co, (HID) for distribution of its hepatitis B product, Sci-B-Vac™, in China which will generate revenue in excess of US\$145 million.

Under the agreement HID is required to order and pay for minimum annual quantities of Sci-B-Vac™, either as dispensed doses or bulk antigen, for seven years. In the former case, the minimum allocation of final product per annum will generate revenues of US\$210 million for SciGen over seven years. For bulk antigen, the seven-year order would total US\$145 million.

“This is a very significant commercial deal for SciGen,” said Saul Mashaal, CEO of SciGen. “The sales targets to which HID has agreed are substantive, yet the agreement allows SciGen considerable control over the future of Sci-B-Vac sales and marketing in China.”

HID has been appointed as the non-exclusive distributor of product to customers in China. SciGen retains the right to sell the product directly in China or to appoint other distributors.

As part of the agreement, the Hefei Economic & Technological Development Area (HETDA) will ensure that SciGen receive all required governmental consents.

About Sci-B-Vac™

Sci-B-Vac™ is a third generation recombinant vaccine produced in mammalian cell culture that contains a mixture of three regions of the hepatitis B virus surface proteins that stimulate a faster immune response than other hepatitis B vaccine presently available. Sci-B-Vac™ has been proven safe and effective after testing in more than 3,500 men, women, children and newborn.

About SciGen

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product



development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices in Australia, USA, Korea, Vietnam, Hong Kong, and Philippines and partners in India, China, Indonesia, Israel, Poland, Austria and the Netherlands.

Further information:

Investor Relations and Media	Company
Rebecca Wilson Buchan Consulting +61 2 9237 2800 +61 417 382 391 (mobile) rwilson@bcg.com.au	Saul Mashaal Executive Vice Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)